Flag of the European Union EU Clinical Trials Register Help

Clinical trials for coronavirus

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44394   clinical trials with a EudraCT protocol, of which   7406   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
    Select Country:
    Select Age Range:
    Select Trial Status:
    Select Trial Phase:
    Select Gender:
    Select Date Range:
    to
    Select Rare Disease:
    IMP with orphan designation in the indication
    Orphan Designation Number:
    Results Status:
    Clear advanced search filters
     
    102 result(s) found for: coronavirus. Displaying page 1 of 6.
    1  2  3  4  5  6  Next»
    EudraCT Number: 2020-003628-18 Sponsor Protocol Number: 000000 Start Date*: 2020-09-29
    Sponsor Name:University of Oxford, Clinical Trials and Research Governance
    Full Title: Adalimumab in COVID-19 to present respiratory failure in community care (AVID-CC): A randomised controlled trial
    Medical condition: COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    20.0 10022891 - Investigations 10070255 Coronavirus test positive PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2020-002110-41 Sponsor Protocol Number: CRUKD/20/002 Start Date*: 2020-06-18
    Sponsor Name:Cancer Research UK
    Full Title: SPIKE-1 TRIAL: A Randomised Phase II/III trial in a community setting, assessing use of camostat in reducing the clinical progression of COVID-19 by blocking SARS-CoV-2 Spike protein-initiated memb...
    Medical condition: COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2020-001996-33 Sponsor Protocol Number: CD12_COVID-19 Start Date*: 2020-08-26
    Sponsor Name:CytoDyn, Inc.
    Full Title: A Phase 2b/3, Randomized, Double Blind, Placebo Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety of Leronlimab for Patients with Severe or Critical Coronavirus Disease 2019 (CO...
    Medical condition: Coronavirus Disease 2019 (COVID-19)
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10053983 Corona virus infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2020-005280-31 Sponsor Protocol Number: INHALAVID Start Date*: 2021-04-21
    Sponsor Name:Fundació Eurecat
    Full Title: Phase IV, single-center, randomized and open-label study to evaluate the impact of early treatment with a combination of an inhaled corticosteroid and a long-acting β2 adrenergic agonist (budesonid...
    Medical condition: Enfermedad en pacientes vulnerables con COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-001643-13 Sponsor Protocol Number: 01.01.20 Start Date*: 2020-05-15
    Sponsor Name:University of Dundee
    Full Title: A randomised double-blind placebo-controlled trial of Brensocatib (INS1007) in patients with severe COVID-19
    Medical condition: COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2020-001209-22 Sponsor Protocol Number: PRINCIPLE Start Date*: 2020-03-26
    Sponsor Name:University of Oxford / Clinical Trials and Research Governance
    Full Title: Platform Randomised trial of INterventions against COVID-19 In older peoPLE
    Medical condition: Suspected COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10053983 Corona virus infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2020-001441-39 Sponsor Protocol Number: VIR20001 Start Date*: 2020-05-12
    Sponsor Name:University of Oxford
    Full Title: Chloroquine/ hydroxychloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting; a randomised, placebo-controlled prophylaxis study (COPCOV)
    Medical condition: COVID-19, acute respiratory illness
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10053983 Corona virus infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-001338-21 Sponsor Protocol Number: I4V-MC-KHAB Start Date*: 2021-11-04
    Sponsor Name:Lilly S.A.
    Full Title: A Multicenter, Open-Label, Pharmacokinetic and Safety Study of Baricitinib in Pediatric Patients from 1 Year to Less Than 18 Years Old Hospitalized with COVID-19
    Medical condition: COVID-19 infection
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-001860-27 Sponsor Protocol Number: UoL001542 Start Date*: 2020-05-12
    Sponsor Name:University of Liverpool
    Full Title: AGILE: Seamless Phase I/IIa Platform for the Rapid Evaluation of Candidates for COVID-19 treatment
    Medical condition: Coronavirus-induced disease (COVID-19) (SARS coronavirus 2, or SARS-CoV-2)
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2020-004719-28 Sponsor Protocol Number: D8850C00003 Start Date*: 2020-11-20
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III Randomized, Double-blind, Placebo-controlled, Multi-center Study in Adults to Determine the Safety and Efficacy of AZD7442, a Combination Product of Two Monoclonal Antibodies (AZD8895 a...
    Medical condition: COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2020-005416-22 Sponsor Protocol Number: GS-US-540-5912 Start Date*: 2021-03-24
    Sponsor Name:Gilead Sciences Inc.
    Full Title: A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Remdesivir in Participants with Severely Reduced Kidney Function who ...
    Medical condition: Coronavirus disease 2019 (COVID-19) in patients with chronic renal impairment
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2020-001803-17 Sponsor Protocol Number: GS-US-540-5823 Start Date*: 2020-07-14
    Sponsor Name:Gilead Sciences Inc.
    Full Title: A Phase 2/3 Single-Arm, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesivir (GS-5734™) in Participants from Birth to < 18 Years of Age with COVID-19
    Medical condition: Coronavirus disease 2019 (COVID-19)
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-001736-95 Sponsor Protocol Number: ACCORD-2-001,Sub002,003,006 Start Date*: 2020-04-28
    Sponsor Name:University Hospital Southampton NHS Foundation Trust
    Full Title: ACCORD 2: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID 19 in Hospitalised Patients
    Medical condition: COVID 19
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2020-001934-37 Sponsor Protocol Number: GLUCOCOVID Start Date*: 2020-05-07
    Sponsor Name:IDIVAL Instituto de Investigación Sanitaria Valdecilla
    Full Title: USE OF CORTICOSTEROIDS IN PATIENTS WITH SARS-COV2 CORONAVIRUS INFECTION (GLUCOCOVID). Pragmatic trial inserted in real practice during a pandemic COVID-19
    Medical condition: SARS-CoV-2 infection (COVID-19)
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-002741-18 Sponsor Protocol Number: GS-US-611-6273 Start Date*: 2022-12-19
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-5245 for the Treatment of COVID-19 in Participants With High-Risk for Disease Progression
    Medical condition: Coronavirus disease 2019 (COVID-19) in patients who have a high risk of developing serious or severe illness
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) HU (Completed) ES (Ongoing) BG (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-001031-27 Sponsor Protocol Number: CQ4COV19 Start Date*: 2020-03-14
    Sponsor Name:FUNDACIÓN FLS DE LUCHA CONTRA EL SIDA, LAS ENFERMEDADES INFECCIOSAS Y LA PROMOCIÓN DE LA SALUD Y LA CIENCIA
    Full Title: Treatment of non-severe confirmed cases of COVID-19 and chemoprophylaxis of their contacts as prevention strategy: a Cluster Randomized Clinical Trial (PEP CoV-2 Study)
    Medical condition: SARS-CoV-2 Respiratory Viral Infection
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    20.0 10022891 - Investigations 10070255 Coronavirus test positive PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-001852-16 Sponsor Protocol Number: 01-04-2020 Start Date*: 2020-07-14
    Sponsor Name:Maxima MC
    Full Title: Effect of Iodine treatment in patiënts with COVID-19 disease
    Medical condition: SARS-CoV-2 infection causing COVID-19 disease
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004863 10022902 Iodide intoxication LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-001517-21 Sponsor Protocol Number: I4V-MC-KHAA Start Date*: 2020-06-30
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Study of Baricitinib in Patients with COVID-19 Infection
    Medical condition: COVID-19 infection
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-001364-29 Sponsor Protocol Number: AdiQure/COVID-19 Start Date*: 2020-04-20
    Sponsor Name:Red Andaluza de Diseño y Traslación de Terapias Avanzadas-Fundación Progreso y Salud
    Full Title: Phase I/II clinical trial to evaluate the safety and efficacy of Allogenic Adipose Tissue-Derived Mesenchymal Stem Cells Expanded in patients with severe COVID-19 pneumonia
    Medical condition: Severe COVID-19 pneumonia
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    20.0 10022891 - Investigations 10070255 Coronavirus test positive PT
    21.1 10021881 - Infections and infestations 10035737 Pneumonia viral PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-004356-16 Sponsor Protocol Number: D8850C00002 Start Date*: 2020-11-18
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III Randomized, Double-blind, Placebo-controlled, Multi-center Study in Adults to Determine the Safety and Efficacy of AZD7442, a Combination Product of Two Monoclonal Antibodies (AZD8895 a...
    Medical condition: COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) FR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Apr 25 22:23:26 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA